Tesaro Inc. (NASDAQ:TSRO) rose 3.3% during mid-day trading on Wednesday . The company traded as high as $92.47 and last traded at $92.27, with a volume of 369,752 shares traded. The stock had previously closed at $89.29.

TSRO has been the subject of a number of research analyst reports. Mizuho restated an “outperform” rating and set a $67.00 price objective on shares of Tesaro in a report on Thursday, June 30th. FBR & Co reiterated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Wells Fargo & Co. reiterated an “outperform” rating on shares of Tesaro in a research note on Thursday, June 30th. Wedbush reiterated an “outperform” rating and issued a $72.00 price target on shares of Tesaro in a research note on Wednesday, April 6th. Finally, Zacks Investment Research upgraded Tesaro from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $76.50.

The firm has a 50 day moving average of $62.98 and a 200-day moving average of $47.01. The firm’s market capitalization is $4.22 billion.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by $0.53. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $2.48 million. During the same period last year, the company earned ($1.30) EPS. On average, equities analysts anticipate that Tesaro Inc. will post ($7.16) EPS for the current fiscal year.

In other Tesaro news, VP Edward C. English sold 7,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $40.75, for a total value of $285,250.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $142,625. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Jeffrey H. Hanke sold 12,500 shares of the firm’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the transaction, the vice president now directly owns 12,500 shares of the company’s stock, valued at $929,375. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Whittier Trust Co. increased its position in shares of Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 220 shares during the last quarter. Rhumbline Advisers increased its position in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares during the last quarter. Bank of Montreal Can increased its position in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of Tesaro during the fourth quarter valued at approximately $1,864,000.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.